Bayer (BAYN) PT Set at €123.00 by Baader Bank

Bayer (FRA:BAYN) received a €123.00 ($143.02) price objective from investment analysts at Baader Bank in a research report issued on Thursday. The firm currently has a “buy” rating on the healthcare company’s stock. Baader Bank’s price target would indicate a potential upside of 61.63% from the stock’s current price.

BAYN has been the subject of a number of other reports. Goldman Sachs Group set a €116.00 ($134.88) price target on shares of Bayer and gave the company a “buy” rating in a research report on Wednesday, September 5th. Barclays set a €105.00 ($122.09) price target on shares of Bayer and gave the company a “buy” rating in a research report on Thursday, September 6th. Sanford C. Bernstein set a €115.00 ($133.72) price target on shares of Bayer and gave the company a “buy” rating in a research report on Monday, August 20th. HSBC set a €82.00 ($95.35) price target on shares of Bayer and gave the company a “neutral” rating in a research report on Monday, August 20th. Finally, Jefferies Financial Group set a €92.00 ($106.98) price target on shares of Bayer and gave the company a “neutral” rating in a research report on Wednesday, August 15th. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of €98.80 ($114.88).

BAYN stock opened at €76.10 ($88.49) on Thursday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: What is a stock split?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply